RECURRENT PANCREATIC CARCINOMA
Clinical trials for RECURRENT PANCREATIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PANCREATIC CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PANCREATIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise in tough pancreatic cancer battle
Disease control OngoingThis study tests whether adding the experimental drug veliparib to standard chemotherapy (FOLFIRI) helps people with metastatic pancreatic cancer live longer. About 123 participants whose cancer returned after initial treatment will be randomly assigned to receive either FOLFIRI …
Matched conditions: RECURRENT PANCREATIC CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
New drug combo targets tough cancers: hope for liver, pancreas, and bile duct tumors
Disease control OngoingThis early-phase study tests a combination of two drugs, guadecitabine and durvalumab, in people with advanced liver, pancreatic, bile duct, or gallbladder cancer that has spread. The main goals are to find the safest dose and see if the drugs can shrink tumors. About 55 particip…
Matched conditions: RECURRENT PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New drug cocktail targets Hard-to-Treat pancreatic cancer
Disease control OngoingThis early-phase study tested a combination of three drugs (gemcitabine, dasatinib, and erlotinib) in 19 patients with advanced pancreatic cancer that had spread or could not be removed by surgery. The main goal was to find the safest dose and check for side effects. Researchers …
Matched conditions: RECURRENT PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Experimental drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of two targeted drugs (vismodegib and erlotinib) with or without a standard chemotherapy drug (gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be surgically removed. The main goal is to find the s…
Matched conditions: RECURRENT PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
Gene test trial aims to outsmart advanced cancers
Knowledge-focused OngoingThis study tests whether analyzing the genes of a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to standard therapy are enrolled. The goal is to see if targe…
Matched conditions: RECURRENT PANCREATIC CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 17, 2026 02:02 UTC